Drug intelligence / Profile preview

lactobacillus reuteri cr20

Development stage: Phase 3
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral, Vaginal, Topical

Overview

Lactobacillus reuteri CR20 is a specific strain of the probiotic bacterium *Lactobacillus reuteri* that was originally isolated from the breast milk of healthy women. [NCT00716183] This strain has been clinically investigated for the treatment of lactational mastitis, an inflammatory condition of the breast. [NCT00716183] As a probiotic, its mechanism of action is multifactorial, involving the modulation of the host's microbiota and immune system. It is believed to competitively inhibit pathogenic bacteria, such as *Staphylococcus*, strengthen the mucosal barrier, and produce antimicrobial compounds like reuterin. [3, 8, 11] By promoting an anti-inflammatory environment, it may help alleviate the symptoms of mastitis. [1, 2, 3] A clinical study evaluated the oral administration of *L. reuteri* CR20 in women with lactational mastitis to assess its impact on clinical signs and the bacterial load in breast milk. [NCT00716183]

Targets

Mucosal Barrier Function

Beyond the preview

Go deeper on lactobacillus reuteri cr20.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on lactobacillus reuteri cr20.

Explore the full profile